mProX™ Human MYLK2 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human MYLK2 Stable Cell Line (S01YF-1023-PY99). Click the button above to contact us or submit your feedback about this product.
Alex Smith (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Taylor Williams (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Reduced sensitivity to CD95L-induced apoptosis is achieved through the attenuation of MYLK2 via RNAi knockdown.
Ref: Fox, Joanna L., et al. "Characterisation of FADD interactome reveals novel insights into FADD recruitment and signalling at the Death Inducing Signalling Complex (DISC)." bioRxiv (2021): 2021-03.
Pubmed: NA
DOI: 10.1101/2021.03.25.436271
Research Highlights
Wang, Zhenyu. et al. "Demethylase FTO inhibits the development of prostate cancer by upregulating EGR2 expression in an m6A manner." Turkish journal of biology = Turk biyoloji dergisi, 2022.
The demethylase protein, fat mass and obesity-associated protein (FTO), has been found to play an important role in various cancers. However, its specific mechanisms in prostate cancer (PCa) remain unclear. As such, this study aimed to further understand the function and mechanisms of FTO in PCa. Through gain-of-function assays and RNA-seq techniques, it was discovered that FTO expression was lower in PCa tissues and cell lines compared to adjacent tissues and normal cells. Overexpression of FTO resulted in reduced proliferation, migration, and invasion capabilities in PCa cells. RNA-seq also revealed that FTO overexpression altered the transcriptome landscape and upregulated EGR2 expression in two PCa cell lines, namely Du145 and PC-3. This overexpression also caused changes in the expression of genes such as MYLK2, DNA2, CDK, and CDC (6, 7, 20, 25, and 45), mainly involved in regulating cell cycle and growth pathways. Furthermore, FTO overexpression was found to reduce the methylation level of EGR2. Knockdown of EGR2 was found to rescue the effects of FTO overexpression on cell proliferation, migration, and invasion in Du145 cells. Moreover, FTO overexpression also showed potential in inhibiting tumor growth and promoting EGR2 protein expression. In conclusion, this study uncovered a previously unknown regulatory mechanism of FTO in PCa, and suggests that it could be a potential therapeutic target for the disease.
Wang, Zhenyu. et al. "Demethylase FTO inhibits the development of prostate cancer by upregulating EGR2 expression in an m6A manner." Turkish journal of biology = Turk biyoloji dergisi, 2022.
Pubmed:
37529797
DOI:
10.55730/1300-0152.2629
Luo, Huiyan. et al. "Comprehensive DNA methylation profiling of COVID-19 and hepatocellular carcinoma to identify common pathogenesis and potential therapeutic targets." Clinical epigenetics, 2023.
The impact of SARS-CoV-2 infection on patients with hepatocellular carcinoma (HCC) may be more severe and complicated as compared to other types of cancer. This can be attributed to various factors, including existing conditions like viral hepatitis and cirrhosis, which are often linked to HCC. In light of this, tailored management strategies may be necessary to improve the overall health outcomes of HCC patients who have contracted the virus.
Luo, Huiyan. et al. "Comprehensive DNA methylation profiling of COVID-19 and hepatocellular carcinoma to identify common pathogenesis and potential therapeutic targets." Clinical epigenetics, 2023.
Pubmed:
37309005
DOI:
10.1186/s13148-023-01515-8
